{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T15:05:37Z","timestamp":1775833537123,"version":"3.50.1"},"reference-count":105,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008444","name":"Parkinson Foundation of United States","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008444","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008771","name":"Tourette Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008771","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014427","name":"Dystonia Coalition","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014427","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008497","name":"Boston Scientific","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Eli Lilly"},{"name":"Impax"},{"name":"Neuroderm"},{"name":"Prilenia"},{"DOI":"10.13039\/100015516","name":"Revance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015516","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University Of Florida Moonshot Grant"},{"name":"University Of Florida Opportunity Grant"},{"name":"Harry T. Mangurian Jr. Foundation"},{"name":"Smallwood Foundation"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurologic Clinics"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.ncl.2020.09.014","type":"journal-article","created":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T22:13:07Z","timestamp":1604700787000},"page":"209-229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["An Update on Botulinum Toxin in Neurology"],"prefix":"10.1016","volume":"39","author":[{"given":"Shannon Y.","family":"Chiu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew R.","family":"Burns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene A.","family":"Malaty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ncl.2020.09.014_bib1","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.316.7125.151c","article-title":"Clostridium botulinum was named because of association with \u201csausage poisoning","author":"Torrens","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.ncl.2020.09.014_bib2","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.53.8.1850","article-title":"Historical aspects of botulinum toxin: Justinus Kerner (1786-1862) and the \u201csausage poison","author":"Erbguth","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2020.09.014_bib3","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp.60.2.151","article-title":"Historical note on the therapeutic use of botulinum toxin in neurological disorders","author":"Erbguth","year":"1996","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.ncl.2020.09.014_bib4","doi-asserted-by":"crossref","DOI":"10.1093\/clinids\/1.4.701","article-title":"A\u00a0new anaerobic bacillus and its relation to botulism","author":"Van Ermengem","year":"1979","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.ncl.2020.09.014_bib5","doi-asserted-by":"crossref","DOI":"10.1353\/pbm.1997.0032","article-title":"Botulinum toxin: the story of its development for the treatment of human disease","author":"Schantz","year":"1997","journal-title":"Perspect Biol Med"},{"issue":"Suppl","key":"10.1016\/j.ncl.2020.09.014_bib6","first-page":"271","article-title":"Double-blind controlled study of botulinum toxin for blepharospasm","volume":"35","author":"Fahn","year":"1985","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2020.09.014_bib7","doi-asserted-by":"crossref","DOI":"10.1017\/S031716710003540X","article-title":"A\u00a0pilot study on the use of botulinum toxin in spasmodic torticollis","author":"Tsui","year":"1985","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.ncl.2020.09.014_bib8","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.37.4.616","article-title":"Botulinum a toxin for cranial-cervicaldystonia: a double-blind, placebo-controlled study","author":"Jankovic","year":"1987","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2020.09.014_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(86)92070-2","article-title":"Double-blind study of botulinum toxin in spasmodic torticollis","author":"Tsui","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.ncl.2020.09.014_bib10","doi-asserted-by":"crossref","DOI":"10.1007\/s00702-015-1478-1","article-title":"Botulinum toxin drugs: brief history and outlook","author":"Dressler","year":"2016","journal-title":"J\u00a0Neural Transm"},{"key":"10.1016\/j.ncl.2020.09.014_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.tins.2005.06.001","article-title":"Beyond BOTOX: Advantages and limitations of individual botulinum neurotoxins","author":"Davletov","year":"2005","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.ncl.2020.09.014_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/1531-8257(199903)14:2<307::AID-MDS1016>3.0.CO;2-3","article-title":"Effect of muscle activity immediately after botulinum toxin injection for writer\u2019s cramp","author":"Chen","year":"1999","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2020.09.014_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/mds.870120115","article-title":"The variability in the clinical effect induced by botulinum toxin type A: The role of muscle activity in humans","author":"Eleopra","year":"1997","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2020.09.014_bib14","series-title":"Extrafusal and intrafusal muscle effects in experimental botulinum toxin-a injection","author":"Rosales","year":"1996"},{"key":"10.1016\/j.ncl.2020.09.014_bib15","doi-asserted-by":"crossref","DOI":"10.1002\/mds.20801","article-title":"Botulinum toxin changes intrafusal feedback in dystonia: a study with the tonic vibration reflex","author":"Trompetto","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2020.09.014_bib16","doi-asserted-by":"crossref","DOI":"10.1113\/jphysiol.2012.239178","article-title":"Beyond muscular effects: depression of spinal recurrent inhibition after botulinum neurotoxin A","author":"Marchand-Pauvert","year":"2013","journal-title":"J\u00a0Physiol"},{"key":"10.1016\/j.ncl.2020.09.014_bib17","doi-asserted-by":"crossref","DOI":"10.1002\/1531-8249(200007)48:1<20::AID-ANA5>3.0.CO;2-U","article-title":"Effects of botulinum toxin type A on intracortical inhibition in patients with dystonia","author":"Gilio","year":"2000","journal-title":"Ann Neurol"},{"key":"10.1016\/j.ncl.2020.09.014_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.resmic.2014.09.007","article-title":"Historical and current perspectives on Clostridium botulinum diversity","author":"Smith","year":"2015","journal-title":"Res Microbiol"},{"key":"10.1016\/j.ncl.2020.09.014_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/mdc3.12235","article-title":"OnabotulinumtoxinA and abobotulinumtoxina dose conversion: a systematic literature review","author":"Dashtipour","year":"2016","journal-title":"Mov Disord Clin Pract"},{"key":"10.1016\/j.ncl.2020.09.014_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/toxins8030065","article-title":"Conversion ratio between Botox\u00ae, Dysport\u00ae, and Xeomin\u00ae in clinical practice","author":"Scaglione","year":"2016","journal-title":"Toxins (Basel)"},{"key":"10.1016\/j.ncl.2020.09.014_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.toxicon.2015.08.001","article-title":"Clinical differences between botulinum neurotoxin type A and B","author":"Bentivoglio","year":"2015","journal-title":"Toxicon"},{"key":"10.1016\/j.ncl.2020.09.014_bib22","series-title":"Package insert, BOTOX (botulinum toxin type A purified neurotoxin complex)","author":"Allergan","year":"2019"},{"key":"10.1016\/j.ncl.2020.09.014_bib23","series-title":"Package insert, XEOMIN (incobotulinumtoxintype A)","author":"Merz Pharmaceuticals","year":"2018"},{"key":"10.1016\/j.ncl.2020.09.014_bib24","series-title":"Package Insert, MYOBLOC (Botulinum toxin type B injectable solution)","author":"Solstice Neurosciences","year":"2019"},{"key":"10.1016\/j.ncl.2020.09.014_bib25","series-title":"Ipsen. Package insert, DYSPORT (abobotulinumtoxinA)","year":"2019"},{"key":"10.1016\/j.ncl.2020.09.014_bib26","doi-asserted-by":"crossref","DOI":"10.1177\/0269215516655589","article-title":"Does the method of botulinum neurotoxin injection for limb spasticity affect outcomes? A systematic review","author":"Chan","year":"2017","journal-title":"Clin Rehabil"},{"key":"10.1016\/j.ncl.2020.09.014_bib27","doi-asserted-by":"crossref","DOI":"10.1007\/s00702-012-0893-9","article-title":"Immunogenicity of botulinum toxins","author":"Naumann","year":"2013","journal-title":"J\u00a0Neural Transm"},{"key":"10.1016\/j.ncl.2020.09.014_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.toxicon.2012.10.020","article-title":"Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disorders","author":"Naumann","year":"2013","journal-title":"Toxicon"},{"key":"10.1016\/j.ncl.2020.09.014_bib29","article-title":"Botulinum toxin type B de novo therapy of cervical dystonia: Frequency of antibody induced therapy failure","author":"Dressler","year":"2005","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.ncl.2020.09.014_bib30","doi-asserted-by":"crossref","DOI":"10.1055\/s-0035-1571210","article-title":"Botulinum toxin treatment of cervical dystonia","author":"Bledsoe","year":"2016","journal-title":"Semin Neurol"},{"key":"10.1016\/j.ncl.2020.09.014_bib31","doi-asserted-by":"crossref","DOI":"10.1111\/j.1468-2982.2009.01941.x","article-title":"Global prevalence of chronic migraine: a systematic review","author":"Natoli","year":"2010","journal-title":"Cephalalgia"},{"key":"10.1016\/j.ncl.2020.09.014_bib32","doi-asserted-by":"crossref","DOI":"10.1177\/0333102410364676","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial","author":"Aurora","year":"2010","journal-title":"Cephalalgia"},{"key":"10.1016\/j.ncl.2020.09.014_bib33","doi-asserted-by":"crossref","DOI":"10.1177\/0333102410364677","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial","author":"Diener","year":"2010","journal-title":"Cephalalgia"},{"key":"10.1016\/j.ncl.2020.09.014_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/toxins10060221","article-title":"Monocentric prospective study into the sustained effect of Incobotulinumtoxin A (XEOMIN\u00ae) botulinum toxin in chronic refractory migraine","author":"Ion","year":"2018","journal-title":"Toxins (Basel)"},{"key":"10.1016\/j.ncl.2020.09.014_bib35","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD011616.pub2","article-title":"Botulinum toxins for the prevention of migraine in adults","author":"Herd","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ncl.2020.09.014_bib36","doi-asserted-by":"crossref","DOI":"10.1111\/j.1526-4610.2010.01766.x","article-title":"Method of injection of onabotulinumtoxina for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the preempt clinical program","author":"Blumenfeld","year":"2010","journal-title":"Headache"},{"key":"10.1016\/j.ncl.2020.09.014_bib37","doi-asserted-by":"crossref","DOI":"10.1111\/ane.12906","article-title":"Botulinum toxin: a review of the mode of action in migraine","author":"Do","year":"2018","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.ncl.2020.09.014_bib38","doi-asserted-by":"crossref","DOI":"10.1212\/01.WNL.0000027361.73814.0E","article-title":"Blepharospasm: recent advances","author":"Hallett","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2020.09.014_bib39","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000002560","article-title":"Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache Report of the Guideline Development Subcommittee of the American Academy of Neurology","author":"Simpson","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2020.09.014_bib40","article-title":"Botulinum toxin treatment of blepharospasm, orofacial\/oromandibular dystonia, and hemifacial spasm","author":"Karp","year":"2016","journal-title":"Semin Neurol"},{"key":"10.1016\/j.ncl.2020.09.014_bib41","doi-asserted-by":"crossref","DOI":"10.1007\/s11136-011-9890-y","article-title":"Factors associated with quality of life in hemifacial spasm and blepharospasm during long-term treatment with botulinum toxin","author":"Setthawatcharawanich","year":"2011","journal-title":"Qual Life Res"},{"key":"10.1016\/j.ncl.2020.09.014_bib42","doi-asserted-by":"crossref","DOI":"10.1111\/j.1468-1331.2010.03161.x","article-title":"Clinical features of patients with blepharospasm: a report of 240 patients","author":"Peckham","year":"2011","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.ncl.2020.09.014_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.toxicon.2012.12.004","article-title":"Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders","author":"Hallett","year":"2013","journal-title":"Toxicon"},{"key":"10.1016\/j.ncl.2020.09.014_bib44","doi-asserted-by":"crossref","DOI":"10.1007\/BF00941758","article-title":"Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm","author":"N\u00fc\u00dfgens","year":"1997","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ncl.2020.09.014_bib45","doi-asserted-by":"crossref","DOI":"10.1007\/s13760-014-0285-z","article-title":"Long-term therapy of benign essential blepharospasm and facial hemispasm with botulinum toxin A: retrospective assessment of the clinical and quality of life impact in patients treated for more than 15 years","author":"Streitov\u00e1","year":"2014","journal-title":"Acta Neurol Belg"},{"key":"10.1016\/j.ncl.2020.09.014_bib46","doi-asserted-by":"crossref","DOI":"10.1002\/mds.870090605","article-title":"\u201cApraxia of lid opening,\u201d a focal eyelid dystonia: clinical study of 32 patients","author":"Krack","year":"1994","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2020.09.014_bib47","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp.60.6.704","article-title":"Pretarsal injection of botulinum toxin for blepharospasm and apraxia of eyelid opening [13]","author":"Jankovic","year":"1996","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.ncl.2020.09.014_bib48","doi-asserted-by":"crossref","DOI":"10.3109\/02688697.2011.641613","article-title":"Safety and effectiveness of microvascular decompression for treatment of hemifacial spasm: a systematic review","author":"Miller","year":"2012","journal-title":"Br J Neurosurg"},{"issue":"9","key":"10.1016\/j.ncl.2020.09.014_bib49","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/mus.880150909","article-title":"Treatment of hemifacial spasm with botulinum toxin","volume":"5","author":"Yoshimura","year":"1992","journal-title":"Muscle Nerve"},{"issue":"5","key":"10.1016\/j.ncl.2020.09.014_bib50","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3346\/jkms.1993.8.5.334","article-title":"Botulinum a toxin treatment of hemifacial spasm and blepharospasm","volume":"8","author":"Park","year":"1993","journal-title":"J\u00a0Korean Med Sci"},{"key":"10.1016\/j.ncl.2020.09.014_bib51","doi-asserted-by":"crossref","DOI":"10.1002\/mds.870120627","article-title":"DYSBOT: A single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A - Dysport and Botox - Assuming a ratio of 4:1","author":"Sampaio","year":"1997","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2020.09.014_bib52","doi-asserted-by":"crossref","DOI":"10.1002\/mds.21435","article-title":"Botulinum toxin type B (Myobloc\u00ae) in subjects with hemifacial spasm: Results from an open-label, dose-escalation safety study","author":"Trosch","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2020.09.014_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.toxicon.2018.02.006","article-title":"Systematic review of botulinum toxin treatment for oromandibular dystonia","author":"Comella","year":"2018","journal-title":"Toxicon"},{"key":"10.1016\/j.ncl.2020.09.014_bib54","doi-asserted-by":"crossref","DOI":"10.1002\/mds.21580","article-title":"Pallidal deep brain stimulation in patients with cranial-cervical dystonia (Meige syndrome)","author":"Ostrem","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2020.09.014_bib55","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.53.9.2102","article-title":"Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up","author":"Tan","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2020.09.014_bib56","doi-asserted-by":"crossref","DOI":"10.1007\/s13311-018-0620-9","article-title":"Pilot single-blind trial of abobotulinumtoxinA in oromandibular dystonia","author":"Scorr","year":"2018","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.ncl.2020.09.014_bib57","doi-asserted-by":"crossref","unstructured":"Cardoso F, Bhidayasiri R, Truong D. Treatment of oromandibular dystonia. In: Truong D, Dressler D, Hallett M, editors. Manual of Botulinum Toxin Therapy. Cambridge Core University Press; 2009. https:\/\/doi.org\/10.1017\/cbo9780511575761.010.","DOI":"10.1017\/CBO9780511575761.010"},{"key":"10.1016\/j.ncl.2020.09.014_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2014.08.013","article-title":"Drooling in Parkinson\u2019s disease: a review","author":"Srivanitchapoom","year":"2014","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.ncl.2020.09.014_bib59","doi-asserted-by":"crossref","DOI":"10.1002\/mds.20793","article-title":"Botulinum toxin type A for drooling in Parkinson\u2019s disease: a double-blind, randomized, placebo-controlled study","author":"Lagalla","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2020.09.014_bib60","doi-asserted-by":"crossref","DOI":"10.1212\/01.WNL.0000101713.81253.4C","article-title":"A\u00a0double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson\u2019s disease","author":"Ondo","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2020.09.014_bib61","doi-asserted-by":"crossref","DOI":"10.1002\/mds.23473","article-title":"Botulinum toxin A versus B in sialorrhea: a prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson\u2019s disease","author":"Guidubaldi","year":"2011","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2020.09.014_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2003.10.012","article-title":"Ultrasound-guided versus \u201cblind\u201d intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson\u2019s disease","author":"Dogu","year":"2004","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.ncl.2020.09.014_bib63","doi-asserted-by":"crossref","DOI":"10.1111\/j.1468-1331.2006.01447.x","article-title":"Botulinum toxin treatment of sialorrhea: comparing different therapeutic preparations","author":"Tan","year":"2006","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.ncl.2020.09.014_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2016.08.014","article-title":"Determinants of disability in cervical dystonia","author":"van den Dool","year":"2016","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.ncl.2020.09.014_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2014.12.030","article-title":"Primary results from the Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE)","author":"Jankovic","year":"2015","journal-title":"J\u00a0Neurol Sci"},{"issue":"1","key":"10.1016\/j.ncl.2020.09.014_bib66","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1212\/CPJ.0000000000000568","article-title":"Management of cervical dystonia with botulinum neurotoxins and EMG\/ultrasound guidance","volume":"9","author":"Castagna","year":"2019","journal-title":"Neurol Clin Pract"},{"key":"10.1016\/j.ncl.2020.09.014_bib67","article-title":"Botulinum toxin type A in the treatment of patients with cervical dystonia","author":"Brashear","year":"2009","journal-title":"Biologics"},{"key":"10.1016\/j.ncl.2020.09.014_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/S1047-9651(03)00045-7","article-title":"Botulinum toxin therapy for cervical dystonia","author":"Walker","year":"2003","journal-title":"Phys Med Rehabil Clin N Am"},{"key":"10.1016\/j.ncl.2020.09.014_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2017.02.042","article-title":"Multicenter observational study of abobotulinumtoxinA neurotoxin in cervical dystonia: The ANCHOR-CD registry","author":"Trosch","year":"2017","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.ncl.2020.09.014_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2011.06.015","article-title":"Treatment of complex cervical dystonia with botulinum toxin: Involvement of deep-cervical muscles may contribute to suboptimal responses","author":"Bhidayasiri","year":"2011","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.ncl.2020.09.014_bib71","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.42.4.878","article-title":"Botulinum toxin injection for spasmodic torticollis: increased magnitude of benefit with electromyographic assistance","author":"Comella","year":"1992","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2020.09.014_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.toxicon.2018.01.018","article-title":"Towards flexible and tailored botulinum neurotoxin dosing regimens for focal dystonia and spasticity \u2013 Insights from recent studies","author":"Wissel","year":"2018","journal-title":"Toxicon"},{"key":"10.1016\/j.ncl.2020.09.014_bib73","article-title":"High-dose botulinum toxin therapy: safety, benefit, and endurance of efficacy","volume":"10","author":"Chiu","year":"2020","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"key":"10.1016\/j.ncl.2020.09.014_bib74","doi-asserted-by":"crossref","DOI":"10.1111\/j.1468-1331.2006.01440.x","article-title":"Treatment of cervical dystonia with botulinum toxins","author":"Comella","year":"2006","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.ncl.2020.09.014_bib75","doi-asserted-by":"crossref","DOI":"10.5334\/tohm.185","article-title":"Botulinum toxin therapy for cervical dystonia: the science of dosing","author":"Evidente","year":"2014","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"key":"10.1016\/j.ncl.2020.09.014_bib76","article-title":"Muscle selection for focal limb dystonia","author":"Karp","year":"2018","journal-title":"Toxins (Basel)"},{"key":"10.1016\/j.ncl.2020.09.014_bib77","doi-asserted-by":"crossref","DOI":"10.1002\/mds.27072","article-title":"Botulinum toxin: state of the art","author":"Jankovic","year":"2017","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2020.09.014_bib78","doi-asserted-by":"crossref","DOI":"10.1080\/01421590701568262","article-title":"Botulinum toxin treatment of axial and cervical dystonia","author":"Benecke","year":"2007","journal-title":"Disabil Rehabil"},{"key":"10.1016\/j.ncl.2020.09.014_bib79","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp.63.6.788","article-title":"Clinical features and natural history of axial predominant adult onset primary dystonia","author":"Bhatia","year":"1997","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.ncl.2020.09.014_bib80","doi-asserted-by":"crossref","DOI":"10.1186\/s40734-016-0044-9","article-title":"The phenomenology and treatment of idiopathic adult-onset truncal dystonia: a retrospective review","author":"Ehrlich","year":"2016","journal-title":"J\u00a0Clin Mov Disord"},{"key":"10.1016\/j.ncl.2020.09.014_bib81","doi-asserted-by":"crossref","DOI":"10.1002\/mds.870130330","article-title":"Extensor truncal dystonia: Successful treatment with botulinum toxin injections","author":"Comella","year":"1998","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2020.09.014_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/S1047-9651(03)00093-7","article-title":"Muscle overactivity and movement dysfunction in the upper motoneuron syndrome","author":"Mayer","year":"2003","journal-title":"Phys Med Rehabil Clin N Am"},{"key":"10.1016\/j.ncl.2020.09.014_bib83","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp.69.2.217","article-title":"Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: A randomised double blind placebo controlled trial","author":"Bhakta","year":"2000","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.ncl.2020.09.014_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.pmrj.2016.06.016","article-title":"OnabotulinumtoxinA injection for poststroke upper-limb spasticity: guidance for early injectors from a Delphi Panel Process","author":"Simpson","year":"2017","journal-title":"PM R"},{"issue":"1","key":"10.1016\/j.ncl.2020.09.014_bib85","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2340\/16501977-0303","article-title":"European consensus table on the use of botulinum toxin type A in adult spasticity","volume":"41","author":"Wissel","year":"2009","journal-title":"J\u00a0Rehabil Med"},{"key":"10.1016\/j.ncl.2020.09.014_bib86","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000003789","article-title":"Safety and efficacy of incobotulinumtoxinA doses up to 800\u00a0U in limb spasticity the TOWER study","author":"Wissel","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2020.09.014_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.pmrj.2017.02.014","article-title":"OnabotulinumtoxinA for lower limb spasticity: guidance from a Delphi Panel Approach","author":"Esquenazi","year":"2017","journal-title":"PM R"},{"key":"10.1016\/j.ncl.2020.09.014_bib88","doi-asserted-by":"crossref","DOI":"10.1055\/s-0035-1571217","article-title":"Botulinum toxin for the treatment of tremor and tics","author":"Lotia","year":"2016","journal-title":"Semin Neurol"},{"key":"10.1016\/j.ncl.2020.09.014_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/S1474-4422(13)70213-8","article-title":"Sensory aspects of movement disorders","author":"Patel","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ncl.2020.09.014_bib90","doi-asserted-by":"crossref","DOI":"10.1007\/s10072-003-0201-4","article-title":"Treatment of phonic tics in patients with Tourette\u2019s syndrome using botulinum toxin type A","author":"Porta","year":"2004","journal-title":"Neurol Sci"},{"key":"10.1016\/j.ncl.2020.09.014_bib91","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.56.5.605","article-title":"Botulinum toxin for simple motor tics: a randomized, double-blind, controlled clinical trial","author":"Marras","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2020.09.014_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2007.10.007","article-title":"Efficacy of botulinum toxin in severe Tourette syndrome with dystonic tics involving the neck","author":"Aguirregomozcorta","year":"2008","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.ncl.2020.09.014_bib93","series-title":"Practice guideline: the treatment of tics in people with Tourette syndrome and chronic tic disorders","year":"2019"},{"key":"10.1016\/j.ncl.2020.09.014_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.toxicon.2017.09.003","article-title":"An update on new and unique uses of botulinum toxin in movement disorders","author":"Jankovic","year":"2018","journal-title":"Toxicon"},{"key":"10.1016\/j.ncl.2020.09.014_bib95","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.41.8.1185","article-title":"Botulinum toxin treatment of tremors","author":"Jankovic","year":"1991","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2020.09.014_bib96","doi-asserted-by":"crossref","DOI":"10.1002\/mds.870110306","article-title":"A\u00a0randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor","author":"Jankovic","year":"1996","journal-title":"Mov Disord"},{"key":"10.1016\/j.ncl.2020.09.014_bib97","doi-asserted-by":"crossref","DOI":"10.3390\/toxins10070299","article-title":"Botulinum toxin for the treatment of hand tremor","author":"Niemann","year":"2018","journal-title":"Toxins (Basel)"},{"key":"10.1016\/j.ncl.2020.09.014_bib98","article-title":"Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology symbol","author":"Simpson","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2020.09.014_bib99","doi-asserted-by":"crossref","DOI":"10.1002\/mdc3.12613","article-title":"Injectable daxibotulinumtoxinA in cervical dystonia: a phase 2 dose-escalation multicenter study","author":"Jankovic","year":"2018","journal-title":"Mov Disord Clin Pract"},{"key":"10.1016\/j.ncl.2020.09.014_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.toxicon.2011.05.012","article-title":"Characterization of diffusion and duration of action of a new botulinum toxin type A formulation","author":"Stone","year":"2011","journal-title":"Toxicon"},{"key":"10.1016\/j.ncl.2020.09.014_bib101","doi-asserted-by":"crossref","DOI":"10.1097\/DSS.0000000000001903","article-title":"Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results from 2 identical phase III studies","author":"Beer","year":"2019","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.ncl.2020.09.014_bib102","doi-asserted-by":"crossref","DOI":"10.3390\/toxins10050208","article-title":"The expanding therapeutic utility of botulinum neurotoxins","author":"Fonfria","year":"2018","journal-title":"Toxins (Basel)"},{"key":"10.1016\/j.ncl.2020.09.014_bib103","doi-asserted-by":"crossref","DOI":"10.1111\/j.1524-4725.2006.32335.x","article-title":"Topically applied botulinum toxin type A for the treatment of primary axillary hyperhidrosis: results of a randomized, blinded, vehicle-controlled study","author":"Glogau","year":"2007","journal-title":"Dermatol Surg"},{"issue":"1","key":"10.1016\/j.ncl.2020.09.014_bib104","first-page":"38","article-title":"Results of a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a botulinum toxin type A topical gel for the treatment of moderate-to-severe lateral canthal lines","volume":"11","author":"Glogau","year":"2012","journal-title":"J\u00a0Drugs Dermatol"},{"key":"10.1016\/j.ncl.2020.09.014_bib105","doi-asserted-by":"crossref","DOI":"10.1093\/asj\/sjw272","article-title":"Liquid formulation of AbobotulinumtoxinA exhibits a favorable efficacy and safety profile in moderate to severe glabellar lines: a randomized, double-blind, placebo- and active comparator-controlled trial","author":"Ascher","year":"2018","journal-title":"Aesthet Surg J"}],"container-title":["Neurologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861920300815?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861920300815?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T10:20:26Z","timestamp":1760005226000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733861920300815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":105,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0733861920300815"],"URL":"https:\/\/doi.org\/10.1016\/j.ncl.2020.09.014","relation":{},"ISSN":["0733-8619"],"issn-type":[{"value":"0733-8619","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An Update on Botulinum Toxin in Neurology","name":"articletitle","label":"Article Title"},{"value":"Neurologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ncl.2020.09.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}